Number of pages: 100 | Report Format: PDF | Published date: March 14, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
According to the deep-dive market assessment study by Growth Plus Reports, the global viral vector & plasmid DNA manufacturing market was valued at US$ 2.86 billion in 2023 and is expected to register a revenue CAGR of 22.23% to reach US$ 14.26 billion by 2031.
Viral Vector & Plasmid DNA Manufacturing Market Fundamentals
Viral vectors and plasmid DNA are extensively used in genetic engineering and gene therapy. Viral vectors are viruses genetically modified to convey genetic material into cells, whereas plasmid DNA is circular DNA that can reproduce independently within a cell. Both methods have important applications in biotechnology and medicine.
Viral vectors are often built from viral genomes that have been altered to remove genes and replace them with therapeutic ones. These vectors can then be used to deliver therapeutic genes to specific cells, such as cancer cells or cells affected by genetic disorders. Retroviruses, adenoviruses, and lentiviruses are common viral vectors.
Plasmid DNA, however, may be utilized in enormous quantities to generate proteins or other molecules of interest. The plasmid DNA is introduced into bacterial cells, duplicating the DNA and obtaining the desired result. Plasmid DNA is also utilized to introduce therapeutic genes into cells in gene therapy.
The production of viral vectors and plasmid DNA includes several phases, including the formation of genetic material, purification, and quality control. The manufacturing process is closely monitored to ensure the finished product’s safety and efficacy. Regulatory bodies, such as the United States Food and Drug Administration (FDA), have set rules for producing and testing viral vectors and plasmid DNA used in human clinical studies.
Viral Vector & Plasmid DNA Manufacturing Market Dynamics
The increasing prevalence of cancer and genetic disorders primarily drives the global viral vector & plasmid DNA manufacturing market. According to the World Health Organization, cancer is the biggest cause of mortality globally, accounting for approximately 10 million deaths in 2020. Chemotherapy, radiation, and surgical excision are some of the typical cancer therapies and treatments available. Yet, if certain cancer cells can evade these therapies, it might result in more aggressive tumors. As a result, these procedures are insufficient. Using DNA molecules for gene therapy is an option with promising outcomes. Plasmids, small circular molecules initially derived from bacteria, are the most often utilized DNA-based vectors for cancer gene therapy and DNA vaccination. Plasmid DNA for gene therapy and DNA vaccination has various benefits over other nucleic acid platforms, including its ease of design and fabrication, cheap production cost, and great transit and long-term storage stability.
Technological advancements in plasmid production are fueling the global viral vector & plasmid DNA manufacturing market revenue growth. Technology has made plasmid creation and the production of viral vectors far more efficient and cost-effective. With developments in processes and technology, it is now possible to create high-quality plasmids in larger quantities in far less time. Moreover, tools like gene cloning can lower the time and expense involved with this process. Additionally, applying modern chemistry and biochemistry techniques has improved the precision and speed of plasmid creation, lowered production costs, and ensured superior outcomes.
The global viral vector & plasmid DNA manufacturing market is also increasing due to the rise in the awareness of gene therapy. For instance, in June 2022, the Alliance for Regenerative Medicine (ARM) announced the formation of the Foundation for Cell & Gene Medicine, which will be dedicated to raising public awareness and understanding of the clinical and societal benefits of cell and gene medicine, such as gene therapy, gene editing, cell therapy, tissue engineering, and organ regeneration, as well as supporting its development through education and research projects. The new Foundation for Cell & Gene Medicine’s mission is to educate, engage, and empower the public and stakeholders on critical scientific, clinical, and regulatory challenges affecting the progress and adoption of cell and gene therapies as viable and revolutionary therapeutic choices.
However, the high cost of gene treatments, the danger of mutagenesis, and other barriers in gene therapy limit the growth of the viral vectors and plasmid DNA manufacturing market to some extent.
Viral Vector & Plasmid DNA Manufacturing Market Ecosystem
The global viral vector & plasmid DNA manufacturing market is analyzed from four perspectives: product type, application, end-use, and region.
Viral Vector & Plasmid DNA Manufacturing Market by Product Type
Based on product type, the global viral vector & plasmid DNA manufacturing market is segmented into plasmid DNA, viral vector, and non-viral vector.
The viral vector segment accounted for the majority of the global viral vector & plasmid DNA manufacturing market revenue share. This is attributed to its importance and relevancy in different research applications. However, the plasmid DNA segment is anticipated to increase in the forecast years. Bacterial plasmids may encode genes for traits that are sometimes beneficial to their hosts, such as antimicrobial resistance, virulence, heavy metal tolerance, and the catabolism of unique nutrient sources. Moreover, plasmids are easier and cheaper to create, transport, and store than viral and RNA-based vectors, and they have a far longer shelf life. Furthermore, plasmid modular structure enables simple molecular cloning, making them simple to modify and create for therapeutic application.
Viral Vector & Plasmid DNA Manufacturing Market by Application
Based on the application, the global viral vector & plasmid DNA manufacturing market is segmented into cancer, infectious diseases, genetic disorders, and others.
The cancer segment dominates the global viral vector & plasmid DNA manufacturing market with the largest revenue share. The segment growth is majorly attributed to the increasing prevalence of cancer and the rising uptake of new treatment procedures in treating cancer. According to GLOBOCAN 2020, there were 1,92,92,789 new cancer cases in 2020, which is expected to rise to 2,88,87,940 by 2040. Treating cancer with viral vector & plasmid DNA is anticipated to be an efficient treatment. Plasmid DNA and viral vector-based cancer vaccines have numerous intrinsic characteristics that make them excellent cancer vaccine applicants. These plasmid DNA and viral vector vaccines deliver tumor-specific antigens and produce a tumor-specific immune response. Additionally, they can carry genes and proteins directly to cells, allowing for regulated expression of these genes and proteins. Viral vector and plasmid DNA may also be modified to target cancer-causing mutations specifically, and the vectors can be changed to be resistant to viral escape mutations. Additionally, viral vector and plasmid DNA are extremely simple to create and may be made to be non-immunogenic and safe. As a result, they are an appealing choice for cancer treatment.
Viral Vector & Plasmid DNA Manufacturing Market by End-use
Based on end-use, the global viral vector & plasmid DNA manufacturing market is segmented into pharmaceutical and biopharmaceutical companies and research institutes.
The research institutes segment accounted for most of the global viral vector & plasmid DNA manufacturing market revenue share in 2022. Research institutes have been using both viral vectors and plasmid DNA for many research studies for many years. Viral vectors have been utilized mainly for the purpose of gene therapy and the delivery of foreign DNA into cells. Plasmid DNA is typically used for gene cloning, gene expression, and drug target discovery. Moreover, research institutes can undertake various in-depth studies that would otherwise be impossible.
The pharmaceutical and biopharmaceutical companies are anticipated to increase in the forecast years. This is owing to the introduction of commonly used advanced therapies and an increase in the number of gene therapy-based discovery programs by companies.
Viral Vector & Plasmid DNA Manufacturing Market by Region
Based on the region, the global viral vector & plasmid DNA manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the viral vector & plasmid DNA manufacturing market with the largest revenue share. This is due to the increasing cancer prevalence and genetic diseases, such as cystic fibrosis. Additionally, the market is also anticipated to increase as R&D activities in the region are increasing. Moreover, the growth of the viral vector & plasmid DNA market in North America is also ascribed to increasing healthcare standards. Collaborations between corporations and other organizations, research institutes, and non-profit organizations to create and produce viral vectors and plasmid DNA are increasing in North America. Dyno Therapeutics, a biotechnology company based in the United States that applies artificial intelligence to gene therapy, collaborated with Novartis in May 2020 to develop improved Adeno-Associated Virus vectors for the research, development, and commercialization of gene therapies for ocular diseases. The collaboration enables novel gene treatments for patients with acute eye diseases by combining Dyno’s CapsidMap artificial intelligence technology with Novartis’ experience in gene therapy research and worldwide commercialization.
The Europe viral vector & plasmid DNA manufacturing market is characterized by the increasing prevalence of cancer and the growing demand for gene therapies. Rising investments and funding for research and development are also increasing the global viral vector & plasmid DNA manufacturing market in Europe. Moreover, the increasing interest of many market players in Europe to manufacture plasmids is another factor anticipated to boost revenue growth in the viral vector & plasmid DNA manufacturing market.
Asia Pacific is predicted to be the fastest-growing geographic region in the viral vector & plasmid DNA manufacturing market. The increasing patient population with cancer and genetic diseases is the key factor supporting the global viral vector & plasmid DNA manufacturing market. Furthermore, increasing government and private organizations funding for research and development is also anticipated to help expand the global viral vector & plasmid DNA manufacturing market in Asia Pacific.
Viral Vector & Plasmid DNA Manufacturing Market Competitive Landscape
Several companies are emphasizing development strategies, such as product launches, product approvals, patents, and events. The market witnessed an increase in acquisition, partnership, and cooperation activities as inorganic development tactics. These initiatives have enabled the expansion of future economic business prospects in the global viral vector & plasmid DNA manufacturing market.
The prominent companies with the largest revenue share in the global viral vector & plasmid DNA manufacturing market are:
Viral Vector & Plasmid DNA Manufacturing Market Strategic Developments
The global viral vector & plasmid DNA manufacturing market is expected to be valued at US$ 14.26 billion by 2031.
Over the years, the viral vector & plasmid DNA manufacturing market has revolutionized research and developments. Moreover, the viral vector & plasmid DNA manufacturing market is also growing as demand for plasmid treatments increases.
The global viral vector & plasmid DNA manufacturing market is expected to register a revenue CAGR of 22.23% by 2031.
Viral vectors and plasmid DNA are two extensively utilized technologies in genetic engineering and gene therapy. Viral vectors are viruses that have been genetically modified to convey genetic material into cells, whereas plasmid DNA is circular DNA that can reproduce independently within a cell. Plasmid DNA, however, may be utilized in enormous quantities to generate proteins or other molecules of interest.
North America accounted for the highest revenue share in the global market in 2022.
*Insights on financial performance are subject to the availability of information in the public domain